Skip to content
News & Publications
News
Publications
Contact Us
About Us
History
Patents
Technology
Signaling Chain HOmoOLigomerization (“SCHOOL”) Platform Basics
Macrophage Modulation
Macrophage Imaging
Pipeline
Therapeutic Areas
Cancer
Autoimmune Diseases
Retinopathy
Atherosclerosis
Sepsis/ARDS & COVID
Other Inflammatory Diseases
Partners & Collaborators
Menu
Understanding Nature. Improving Life
Type and press enter to search
SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new therapy for rheumatoid arthritis
SignaBlok
>
News
>
SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new therapy for rheumatoid arthritis
SignaBlok
>
News
>
SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new therapy for rheumatoid arthritis
SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new therapy for rheumatoid arthritis
Post navigation
Previous Post
Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy
Next Post
SignaBlok presented preclinical data showcasing company’s peptide therapeutic programs in cancer, inflammation and autoimmune diseases at the 2015 Therapeutics Stream at the Essential Protein Engineering Summit (PEGS) Annual Meeting
Vera
View posts by Vera
Scroll to top
close ×
